Barinthus Biotherapeutics plc
BRNS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.07 | 0.13 | -0.00 |
| FCF Yield | -21.10% | -48.35% | -38.06% | 26.90% |
| EV / EBITDA | 0.88 | 1.92 | 2.72 | 2.67 |
| Quality | ||||
| ROIC | -14.93% | -19.60% | -15.59% | -15.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.86 | 0.76 | -0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 3.70% | -20.82% | -30.56% |
| Free Cash Flow Growth | 40.87% | -21.69% | -216.39% | 169.94% |
| Safety | ||||
| Net Debt / EBITDA | 4.67 | 3.88 | 4.95 | 5.15 |
| Interest Coverage | -1,158.92 | -1,943.67 | -1,584.62 | -1,949.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |